#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Comprehensive approach in the management of patients with diabesity


Authors: Ľubomíra Fábryová
Authors‘ workplace: Metabol KLINIK s. r. o., Bratislava – Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, Špecializovaná lipidologická ambulancia, MED PED centrum
Published in: Forum Diab 2018; 7(1): 23-33
Category:

Overview

Obesity is currently a global epidemic (pandemic) and the most common metabolic disorder affecting not only adults but also children and adolescents worldwide. Together with the increase in obesity, the number of type 2 diabetic patients is increasing, and we are talking about diabesity, which is becoming a real problem in our clinical practice. Weight reduction leads to significant improvement in cardiometabolic risk factors in obese type 2 diabetics. The current recommendations for the treatment of obese diabetic patients call for complex personalized medicine: the combination of non-pharmacological treatment (diet, physical activity, behavioral therapy), medication treatment (antidiabetic drugs, antiobesity drugs), but in the indicated cases also bariatric/metabolic surgery.

Key words:
antidiabetics, antiobesity therapy, bariatric/metabolic surgery, diabesity, no­n-pharmacological therapy obesity, overweight

Received:
14. 1. 2018

Accepted:
5. 2. 2018


Sources

1. Národné centrum zdravotníckych informácií. Činnosť diabetologických ambulancií 2016. ZŠ-11/2017. Dostupné z WWW: <http://www.nczi.sk>.

2. Fábryová Ľ. Farmakologická liečba obézneho diabetika 2. typu. In: Krahulec B, Fábryová Ľ, Holéczy P (eds) et al. Klinická obezitológia. Facta Medica: Brno 2013: 191–200. ISBN 978–80–904731–7-1.

3. Uerlich MF, Yumuk V, Finer N et al. Obesity Management in Europe: Current Status and Objectives for the Future. Obes Facts 2016; 9(4): 273–283. Dostupné z DOI: <http://dx.doi.org/10.1159/000445192>.

4. Hainer V, Tsigos C, Toplak H et al. Comment on the Paper by Uerlich et al: Obesity Management in Europe: Current Status and Objectivs for th Future. Obesity Facts 2016; 9(4): 273–283. Obes Facts 2016; 9(6): 392–396. Dostupné z DOI: <http://dx.doi.org/10.1159/000452249>.

5. Fábryová Ľ. Súčasná situácia v manažmente obéznych pacientov na Slovensku. Koncept národného komplexného manažmentu obezity v Slovenskej republike. Via Pract 2017; 14(6): 279–285.

6. Smatana M, Pažitný P, Kandilaki D et al. Slovakia: Health system review.Health Systems in Transition 2016; 18(6): 1–210. Dostupné z WWW: <http://www.healthobservatory.eu>.

7. Avdičová M, Francisciová K, Ďateľová M et al. Monitorovanie rizikových faktorov chronických chorôb v SR. Regionálny úrad verejného zdravotníctva so sídlom v Banskej Bystrici za podpory Svetovej zdravotníckej organizácie – regionálnej úradovne v Kodani, 2012. ISBN 978–80–971096–0-8.

8. Professional Practice Committee: Standards of Medical Care in Diabetes 2018. Diabetes Care 2018; 41(Suppl 1):S3. Dostupné z DOI: <https://doi.org/10.2337/dc18-SPPC01>.

9. Knowler WC, Barrett-Connor E, Fowler SE et al. [Diabetes Prevention Program Research Group]. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl JMed 2002; 346(6): 393–403. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa012512>.

10. [UK Prospective Diabetes Study 7]. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990; 39(9): 905–912.

11. Rothberg AE, McEwen LN, Kraftson AT et al. Very-low-energy diet for type 2 diabetes: an underutilized therapy? J Diabetes Complications 2014; 28(4): 506–510. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2014.03.014>.

12. Wing RR, Bolin P, Brancati FL et al. LookmAHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369(2): 145–154. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1212914>. Erratum in N Engl J Med 2014; 370(19): 1866.

13. [Look AHEAD Research Group]. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring) 2014; 22(1): 5–13. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.20662>.

14. Gudzune KA, Doshi RS, Mehta AK et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med 2015;162(7): 501–512. Dostupné z DOI: <http://dx.doi.org/10.7326/M14–2238>. Erratum in Correction: Efficacy of commercial weight-loss programs. [Ann Intern Med 2015]

15. Cai X, Yang W, Gao X et al. Baseline body mass index and the efficacy of hypoglycemic treatment in type 2 diabetes: a metaanalysis. PLoS One 2016; 11(12): e0166625. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0166625>.

16. Fábryová Ľ. Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients. J Obes Weight Loss Ther 2015; 5: 277. Dostupné z DOI: <http://dx.doi.org/10.4172/2165–7904.1000277>.

17. Liu SC, Tu YK, Chien MN et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012; 14(9): 810–820. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2012.01606.x>.

18. Lorenz M, Evers A, Wagner M et al. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 2013; 23(14):4011–4018. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bmcl.2013.05.022>.

19. Schroner Z, Uličiansky V. Liečba diabetes mellitus 2. typu založená na účinku inkretínov. 2. ed. SchronerMED: Košice 2011. ISBN 9788097071479.

20. Schroner Z, Uličiansky V. Inhibítory SGLT2 – nová cesta v liečbe diabetes mellitus 2. typu. SchronerMED: Košice 2015. ISBN 978–80–8129–040–4.

21. De Fronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017; 19(10) :1353–1362. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12982>.

22. Tkáč I. Miesto agnistov GLP-1 receptorov a inhibítorov SGLT2 v modernej liečbe diabetu 2. typu. Diabetes a obezita 2017; 34: 17–24.

23. Fried M, Yumuk V, Oppert JM et al. [European Association for the Study of Obesity; International Federation for the Surgery of Obesity – European Chapter]. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Facts 2013; 6(5): 449–468. Dostupné z DOI: <http://dx.doi.org/10.1159/000355480>.

24. Toplak H, Woodward E, Yumuk V. et al. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs. Obes Facts 2015; 8(3): 166–174. Dostupné z DOI: <http://dx.doi.org/10.1159/000430801>.

25. Fábryová Ľ. Účinnosť a bezpečnosť moderných antiobezitík: najnovšie dôkazy a manažment pacientov. Interná Med 2016; 16 (11): 447–454.

26. Ali KF, Shukla AP, Aronne LJ. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.Expert Rev Clin Pharmacol. 2016; 9(1): 27–34. Dostupné z DOI: <http://dx.doi.org/10.1586/17512433.2016.1100072>.

27. Greenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376(9741): 595–605. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)60888–4>. Erratum in Lancet 2010; 376(9741): 594. Lancet 2010; 376(9750): 1392.

28. Apovian CM, AronneL, Rubino D et al. COR-II Study Group. A randomized, phase 3 trial of naltrexoneSR/bupropôion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013; 21(5): 935–943. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.20309>.

29. Hollande P, Gupta AK, Plodkowski R et al. [COR-Diabetes Study Group]. Effects of naltrexone/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013: 36(12): 4022–4029. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–0234. Erratum in Diabetes Care 2014; 37(2): 587.

30. Wadden TA, Foreyt JP, Foster GD et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR–BMOD Trial. Obesity (Silver Spring) 2011;19(1):110–120. Dostupné z DOI:

31. Consensus Development Conference Panel. NIH conference. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991; 115(12): 956–961.

32. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis. Diabetes Care 2016; 39(6): 884–892. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–0351>.

33. Batterham RL, Cummings DE. Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. Diabetes Care 2016;39(6):893–901. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–0145>.

34. Rubino F, Kaplan LM, Schauer PRet al. [Diabetes Surgery Summit Delegates]. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010; 251(3): 399–405. Dostupné z DOI: <http://dx.doi.org/10.1097/SLA.0b013e3181be34e7>.

35. Cummings DE, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2014;2(2):175–181.Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(13)70198–0>.

36. Rubino F, Nathan DM, Eckel RH et al. [Delegates of the 2nd Diabetes Surgery Summit]. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016; 39(6): 861–877. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–0236>.

37. Holéczy P. Metabolická chirurgia – chirurgia obezity. Via Pract 2016; 13(1): 8–12. Dostupné z WWW: <http://obesitas.sk/wp-content/uploads/2016/08/VIA_1_2016_final_holeczy.pdf>.

38. Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol 2015;11(8): 465–477. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2015.84>.

39. Sjöström L, Peltonen M, Jacobson P et al.Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications. JAMA 2014; 311(22): 2297–2304. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.5988>.

40. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273(3): 219–234. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.12012>.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#